How personal loss and hope drove Elaine Maynard’s work in clinical trials and patient-centric technologies

Citius Pharma receives FDA approval for immunotherapy targeting rare blood cancer

Halda Therapeutics raises $126M to take 'hold and kill' precision cancer drugs to the clinic

Gilead gains accelerated FDA approval for rare liver disease treatment

FDA lifts hold on BioNTech and MediLink's ADC trial After safety revisions

Breakthrough delivery system could transform Alzheimer’s treatment

First bispecific CAR-T therapy for MS receives green light from FDA to start phase 1

Breaking News: Lecanemab approved in UK but unavailable on NHS

Highlights

array(40) {
  [0]=>
  string(4) "5789"
  ["article_id"]=>
  string(4) "5789"
  [1]=>
  string(81) "Axcella achieves initial milestones with its hematology product candidate AXA4010"
  ["article_title"]=>
  string(81) "Axcella achieves initial milestones with its hematology product candidate AXA4010"
  [2]=>
  string(155) "Mechanistic data on AXA4010 will be presented at the American Society of Hematology’s (ASH) 2019 Annual Meeting. Additionally, the company has initi"
  ["short_description"]=>
  string(155) "Mechanistic data on AXA4010 will be presented at the American Society of Hematology’s (ASH) 2019 Annual Meeting. Additionally, the company has initi"
  [3]=>
  string(634) "
Mechanistic data on AXA4010 will be presented at the American Society of Hematology’s (ASH) 2019 Annual Meeting. Additionally, the company has initiated enrollment of subjects with sickle cell 
&#nl
The post Axcella achieves initial milestones with its hematology product candidate AXA4010 appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(634) "
Mechanistic data on AXA4010 will be presented at the American Society of Hematology’s (ASH) 2019 Annual Meeting. Additionally, the company has initiated enrollment of subjects with sickle cell 
&#nl
The post Axcella achieves initial milestones with its hematology product candidate AXA4010 appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(134) "https://www.pharmaceutical-business-review.com/news/axcella-achieves-initial-milestones-with-its-hematology-product-candidate-axa4010/"
  ["blog_url"]=>
  string(134) "https://www.pharmaceutical-business-review.com/news/axcella-achieves-initial-milestones-with-its-hematology-product-candidate-axa4010/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-11-08 13:13:54"
  ["create_at"]=>
  string(19) "2019-11-08 13:13:54"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Axcella achieves initial milestones with its hematology product candidate AXA4010

Mechanistic data on AXA4010 will be presented at the American Society of Hematology’s (ASH) 2019 Annual Meetin

array(40) {
  [0]=>
  string(4) "5790"
  ["article_id"]=>
  string(4) "5790"
  [1]=>
  string(71) "Regeneron, Vyriad sign deal to develop oncolytic virus-based treatments"
  ["article_title"]=>
  string(71) "Regeneron, Vyriad sign deal to develop oncolytic virus-based treatments"
  [2]=>
  string(155) "Both firms will also sign a five-year research agreement to use Regeneron’s VelociSuite technologies to jointly design and validate Vesicular Stomat"
  ["short_description"]=>
  string(155) "Both firms will also sign a five-year research agreement to use Regeneron’s VelociSuite technologies to jointly design and validate Vesicular Stomat"
  [3]=>
  string(591) "
Both firms will also sign a five-year research agreement to use Regeneron’s VelociSuite technologies to jointly design and validate Vesicular Stomatitis Virus (VSV)-based oncolytic virus treatments. Under the 
&#nl
The post Regeneron, Vyriad sign deal to develop oncolytic virus-based treatments appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(591) "
Both firms will also sign a five-year research agreement to use Regeneron’s VelociSuite technologies to jointly design and validate Vesicular Stomatitis Virus (VSV)-based oncolytic virus treatments. Under the 
&#nl
The post Regeneron, Vyriad sign deal to develop oncolytic virus-based treatments appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(85) "https://www.pharmaceutical-business-review.com/news/regeneron-vyriad-oncolytic-virus/"
  ["blog_url"]=>
  string(85) "https://www.pharmaceutical-business-review.com/news/regeneron-vyriad-oncolytic-virus/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-11-08 13:13:54"
  ["create_at"]=>
  string(19) "2019-11-08 13:13:54"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Regeneron, Vyriad sign deal to develop oncolytic virus-based treatments

Both firms will also sign a five-year research agreement to use Regeneron’s VelociSuite technologies to jointl

array(40) {
  [0]=>
  string(4) "5814"
  ["article_id"]=>
  string(4) "5814"
  [1]=>
  string(139) "SOTIO exercises second target option under existing collaboration with NBE-Therapeutics to develop next-generation antibody-drug conjugates"
  ["article_title"]=>
  string(139) "SOTIO exercises second target option under existing collaboration with NBE-Therapeutics to develop next-generation antibody-drug conjugates"
  [2]=>
  string(150) "Basel, Switzerland & Prague, Czech Republic – November 7, 2019 – NBE-Therapeutics AG and SOTIO a.s. today announced that SOTIO has ele"
  ["short_description"]=>
  string(150) "Basel, Switzerland & Prague, Czech Republic – November 7, 2019 – NBE-Therapeutics AG and SOTIO a.s. today announced that SOTIO has ele"
  [3]=>
  string(603) "Basel, Switzerland & Prague, Czech Republic – November 7, 2019 – NBE-Therapeutics AG and SOTIO a.s. today announced that SOTIO has elected a second target for the development of a next generation antibody-drug conjugate (ADC) under their existing license and collaboration agreement. NBE and SOTIO will collaborate on the discovery, non-clinical development and manufacturing of this second undisclosed target. The development will be based on NBE’s proprietary antibody drug conjugate platform, including NBE’s site-specific SMAC-technology™...&#nl&#nlSource: RealWire"
  ["description"]=>
  string(603) "Basel, Switzerland & Prague, Czech Republic – November 7, 2019 – NBE-Therapeutics AG and SOTIO a.s. today announced that SOTIO has elected a second target for the development of a next generation antibody-drug conjugate (ADC) under their existing license and collaboration agreement. NBE and SOTIO will collaborate on the discovery, non-clinical development and manufacturing of this second undisclosed target. The development will be based on NBE’s proprietary antibody drug conjugate platform, including NBE’s site-specific SMAC-technology™...&#nl&#nlSource: RealWire"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "64"
  ["rss_id"]=>
  string(2) "64"
  [14]=>
  string(107) "http://www.realwire.com/releases/SOTIO-exercises-second-target-option-under-existing-collaboration-with-NBE"
  ["blog_url"]=>
  string(107) "http://www.realwire.com/releases/SOTIO-exercises-second-target-option-under-existing-collaboration-with-NBE"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-11-08 13:14:44"
  ["create_at"]=>
  string(19) "2019-11-08 13:14:44"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

SOTIO exercises second target option under existing collaboration with NBE-Therapeutics to

Basel, Switzerland & Prague, Czech Republic – November 7, 2019 – NBE-Therapeutics AG and SOTIO a.s. toda

array(40) {
  [0]=>
  string(4) "5879"
  ["article_id"]=>
  string(4) "5879"
  [1]=>
  string(140) "Roxadustat significantly increased hemoglobin levels for chronic kidney disease patients with anemia in phase III OLYMPUS and ROCKIES trials"
  ["article_title"]=>
  string(140) "Roxadustat significantly increased hemoglobin levels for chronic kidney disease patients with anemia in phase III OLYMPUS and ROCKIES trials"
  [2]=>
  string(150) "The OLYMPUS trial compared roxadustat to placebo while the ROCKIES trial compared roxadustat to epoetin alfa. The results were presented today during "
  ["short_description"]=>
  string(150) "The OLYMPUS trial compared roxadustat to placebo while the ROCKIES trial compared roxadustat to epoetin alfa. The results were presented today during "
  [3]=>
  string(736) "
The OLYMPUS trial compared roxadustat to placebo while the ROCKIES trial compared roxadustat to epoetin alfa. The results were presented today during two oral sessions at the American 
&#nl
The post Roxadustat significantly increased hemoglobin levels for chronic kidney disease patients with anemia in phase III OLYMPUS and ROCKIES trials appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(736) "
The OLYMPUS trial compared roxadustat to placebo while the ROCKIES trial compared roxadustat to epoetin alfa. The results were presented today during two oral sessions at the American 
&#nl
The post Roxadustat significantly increased hemoglobin levels for chronic kidney disease patients with anemia in phase III OLYMPUS and ROCKIES trials appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(193) "https://www.pharmaceutical-business-review.com/news/roxadustat-significantly-increased-hemoglobin-levels-for-chronic-kidney-disease-patients-with-anemia-in-phase-iii-olympus-and-rockies-trials/"
  ["blog_url"]=>
  string(193) "https://www.pharmaceutical-business-review.com/news/roxadustat-significantly-increased-hemoglobin-levels-for-chronic-kidney-disease-patients-with-anemia-in-phase-iii-olympus-and-rockies-trials/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-11-11 12:48:53"
  ["create_at"]=>
  string(19) "2019-11-11 12:48:53"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Roxadustat significantly increased hemoglobin levels for chronic kidney disease patients w

The OLYMPUS trial compared roxadustat to placebo while the ROCKIES trial compared roxadustat to epoetin alfa. The res

array(40) {
  [0]=>
  string(4) "5880"
  ["article_id"]=>
  string(4) "5880"
  [1]=>
  string(62) "Johnson & Johnson seeks EMA approval for Ebola vaccine regimen"
  ["article_title"]=>
  string(62) "Johnson & Johnson seeks EMA approval for Ebola vaccine regimen"
  [2]=>
  string(150) "The company has submitted marketing authorisation applications (MAAs) to the EMA to prevent Ebola Virus Disease (EVD) caused by Zaire ebolavirus speci"
  ["short_description"]=>
  string(150) "The company has submitted marketing authorisation applications (MAAs) to the EMA to prevent Ebola Virus Disease (EVD) caused by Zaire ebolavirus speci"
  [3]=>
  string(556) "
The company has submitted marketing authorisation applications (MAAs) to the EMA to prevent Ebola Virus Disease (EVD) caused by Zaire ebolavirus species. Janssen has submitted two MAAs in 
&#nl
The post Johnson & Johnson seeks EMA approval for Ebola vaccine regimen appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(556) "
The company has submitted marketing authorisation applications (MAAs) to the EMA to prevent Ebola Virus Disease (EVD) caused by Zaire ebolavirus species. Janssen has submitted two MAAs in 
&#nl
The post Johnson & Johnson seeks EMA approval for Ebola vaccine regimen appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(82) "https://www.pharmaceutical-business-review.com/news/johnson-johnson-ebola-vaccine/"
  ["blog_url"]=>
  string(82) "https://www.pharmaceutical-business-review.com/news/johnson-johnson-ebola-vaccine/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-11-11 12:48:53"
  ["create_at"]=>
  string(19) "2019-11-11 12:48:53"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Johnson & Johnson seeks EMA approval for Ebola vaccine regimen

The company has submitted marketing authorisation applications (MAAs) to the EMA to prevent Ebola Virus Disease (EVD)

array(40) {
  [0]=>
  string(4) "5881"
  ["article_id"]=>
  string(4) "5881"
  [1]=>
  string(98) "Takeda’s dengue vaccine candidate demonstrates protection in children ages four to 16 years"
  ["article_title"]=>
  string(98) "Takeda’s dengue vaccine candidate demonstrates protection in children ages four to 16 years"
  [2]=>
  string(155) "Takeda’s dengue vaccine candidate demonstrated protection against virologically-confirmed dengue (VCD), the trial primary endpoint, in children ages"
  ["short_description"]=>
  string(155) "Takeda’s dengue vaccine candidate demonstrated protection against virologically-confirmed dengue (VCD), the trial primary endpoint, in children ages"
  [3]=>
  string(682) "
Takeda’s dengue vaccine candidate demonstrated protection against virologically-confirmed dengue (VCD), the trial primary endpoint, in children ages four to 16 years. Vaccine efficacy (VE) was 80.2% (95% confidence 
&#nl
The post Takeda’s dengue vaccine candidate demonstrates protection in children ages four to 16 years appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(682) "
Takeda’s dengue vaccine candidate demonstrated protection against virologically-confirmed dengue (VCD), the trial primary endpoint, in children ages four to 16 years. Vaccine efficacy (VE) was 80.2% (95% confidence 
&#nl
The post Takeda’s dengue vaccine candidate demonstrates protection in children ages four to 16 years appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(143) "https://www.pharmaceutical-business-review.com/news/takedas-dengue-vaccine-candidate-demonstrates-protection-in-children-ages-four-to-16-years/"
  ["blog_url"]=>
  string(143) "https://www.pharmaceutical-business-review.com/news/takedas-dengue-vaccine-candidate-demonstrates-protection-in-children-ages-four-to-16-years/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-11-11 12:48:53"
  ["create_at"]=>
  string(19) "2019-11-11 12:48:53"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Takeda’s dengue vaccine candidate demonstrates protection in children ages four to

Takeda’s dengue vaccine candidate demonstrated protection against virologically-confirmed dengue (VCD), the tr

array(40) {
  [0]=>
  string(4) "6069"
  ["article_id"]=>
  string(4) "6069"
  [1]=>
  string(80) "GSK’s mepolizumab succeeds in phase 3 trial in hypereosinophilic syndrome"
  ["article_title"]=>
  string(80) "GSK’s mepolizumab succeeds in phase 3 trial in hypereosinophilic syndrome"
  [2]=>
  string(150) "The late-stage study evaluated subcutaneously administered mepolizumab 300mg (3x100mg) every four weeks against placebo in 108 adolescent and adult pa"
  ["short_description"]=>
  string(150) "The late-stage study evaluated subcutaneously administered mepolizumab 300mg (3x100mg) every four weeks against placebo in 108 adolescent and adult pa"
  [3]=>
  string(578) "
The late-stage study evaluated subcutaneously administered mepolizumab 300mg (3x100mg) every four weeks against placebo in 108 adolescent and adult patients with severe HES. The HES trial met its 
&#nl
The post GSK’s mepolizumab succeeds in phase 3 trial in hypereosinophilic syndrome appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(578) "
The late-stage study evaluated subcutaneously administered mepolizumab 300mg (3x100mg) every four weeks against placebo in 108 adolescent and adult patients with severe HES. The HES trial met its 
&#nl
The post GSK’s mepolizumab succeeds in phase 3 trial in hypereosinophilic syndrome appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(83) "https://www.pharmaceutical-business-review.com/news/gsks-mepolizumab-phase-3-trial/"
  ["blog_url"]=>
  string(83) "https://www.pharmaceutical-business-review.com/news/gsks-mepolizumab-phase-3-trial/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-11-15 05:49:10"
  ["create_at"]=>
  string(19) "2019-11-15 05:49:10"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

GSK’s mepolizumab succeeds in phase 3 trial in hypereosinophilic syndrome

The late-stage study evaluated subcutaneously administered mepolizumab 300mg (3x100mg) every four weeks against place

array(40) {
  [0]=>
  string(4) "6070"
  ["article_id"]=>
  string(4) "6070"
  [1]=>
  string(82) "Finch Therapeutics, Takeda expand collaboration to develop microbiome therapeutics"
  ["article_title"]=>
  string(82) "Finch Therapeutics, Takeda expand collaboration to develop microbiome therapeutics"
  [2]=>
  string(160) "Under the terms of the expanded agreement, Finch and Takeda will utilize Finch’s platform to target Crohn’s disease, a form of inflammatory bowel "
  ["short_description"]=>
  string(160) "Under the terms of the expanded agreement, Finch and Takeda will utilize Finch’s platform to target Crohn’s disease, a form of inflammatory bowel "
  [3]=>
  string(650) "
Under the terms of the expanded agreement, Finch and Takeda will utilize Finch’s platform to target Crohn’s disease, a form of inflammatory bowel disease. Finch’s Human-First Discovery platform 
&#nl
The post Finch Therapeutics, Takeda expand collaboration to develop microbiome therapeutics appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(650) "
Under the terms of the expanded agreement, Finch and Takeda will utilize Finch’s platform to target Crohn’s disease, a form of inflammatory bowel disease. Finch’s Human-First Discovery platform 
&#nl
The post Finch Therapeutics, Takeda expand collaboration to develop microbiome therapeutics appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(134) "https://www.pharmaceutical-business-review.com/news/finch-therapeutics-takeda-expand-collaboration-to-develop-microbiome-therapeutics/"
  ["blog_url"]=>
  string(134) "https://www.pharmaceutical-business-review.com/news/finch-therapeutics-takeda-expand-collaboration-to-develop-microbiome-therapeutics/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-11-15 05:49:10"
  ["create_at"]=>
  string(19) "2019-11-15 05:49:10"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Finch Therapeutics, Takeda expand collaboration to develop microbiome therapeutics

Under the terms of the expanded agreement, Finch and Takeda will utilize Finch’s platform to target Crohnâ€

array(40) {
  [0]=>
  string(4) "6071"
  ["article_id"]=>
  string(4) "6071"
  [1]=>
  string(50) "RDD Pharma signs LOI to acquire Naia Rare Diseases"
  ["article_title"]=>
  string(50) "RDD Pharma signs LOI to acquire Naia Rare Diseases"
  [2]=>
  string(150) "Closing of the transaction is anticipated to occur after the consummation of the proposed merger of RDD and Innovate Biopharmaceuticals, Inc. (Nasdaq:"
  ["short_description"]=>
  string(150) "Closing of the transaction is anticipated to occur after the consummation of the proposed merger of RDD and Innovate Biopharmaceuticals, Inc. (Nasdaq:"
  [3]=>
  string(556) "
Closing of the transaction is anticipated to occur after the consummation of the proposed merger of RDD and Innovate Biopharmaceuticals, Inc. (Nasdaq: INNT) which will form a combined 
&#nl
The post RDD Pharma signs LOI to acquire Naia Rare Diseases appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(556) "
Closing of the transaction is anticipated to occur after the consummation of the proposed merger of RDD and Innovate Biopharmaceuticals, Inc. (Nasdaq: INNT) which will form a combined 
&#nl
The post RDD Pharma signs LOI to acquire Naia Rare Diseases appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(103) "https://www.pharmaceutical-business-review.com/news/rdd-pharma-signs-loi-to-acquire-naia-rare-diseases/"
  ["blog_url"]=>
  string(103) "https://www.pharmaceutical-business-review.com/news/rdd-pharma-signs-loi-to-acquire-naia-rare-diseases/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-11-15 05:49:10"
  ["create_at"]=>
  string(19) "2019-11-15 05:49:10"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

RDD Pharma signs LOI to acquire Naia Rare Diseases

Closing of the transaction is anticipated to occur after the consummation of the proposed merger of RDD and Innovate 

array(40) {
  [0]=>
  string(4) "6072"
  ["article_id"]=>
  string(4) "6072"
  [1]=>
  string(48) "Merck to acquire Calporta Therapeutics for $576m"
  ["article_title"]=>
  string(48) "Merck to acquire Calporta Therapeutics for $576m"
  [2]=>
  string(150) "The transaction includes an upfront payment and contingent milestone payments. Calporta is involved in the development of selective small-molecule ago"
  ["short_description"]=>
  string(150) "The transaction includes an upfront payment and contingent milestone payments. Calporta is involved in the development of selective small-molecule ago"
  [3]=>
  string(569) "
The transaction includes an upfront payment and contingent milestone payments. Calporta is involved in the development of selective small-molecule agonists to TRPML1 (transient receptor potential cation channel, mucolipin 
&#nl
The post Merck to acquire Calporta Therapeutics for $576m appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(569) "
The transaction includes an upfront payment and contingent milestone payments. Calporta is involved in the development of selective small-molecule agonists to TRPML1 (transient receptor potential cation channel, mucolipin 
&#nl
The post Merck to acquire Calporta Therapeutics for $576m appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(80) "https://www.pharmaceutical-business-review.com/news/merck-calporta-therapeutics/"
  ["blog_url"]=>
  string(80) "https://www.pharmaceutical-business-review.com/news/merck-calporta-therapeutics/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-11-15 05:49:10"
  ["create_at"]=>
  string(19) "2019-11-15 05:49:10"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Merck to acquire Calporta Therapeutics for $576m

The transaction includes an upfront payment and contingent milestone payments. Calporta is involved in the developmen

array(40) {
  [0]=>
  string(4) "6073"
  ["article_id"]=>
  string(4) "6073"
  [1]=>
  string(52) "Lupin to sell its stake in Kyowa to Unison for $526m"
  ["article_title"]=>
  string(52) "Lupin to sell its stake in Kyowa to Unison for $526m"
  [2]=>
  string(150) "Founded in 1998, Unison is an independent private equity firm investing in the healthcare sector across Japan, Korea and Singapore, with an emphasis o"
  ["short_description"]=>
  string(150) "Founded in 1998, Unison is an independent private equity firm investing in the healthcare sector across Japan, Korea and Singapore, with an emphasis o"
  [3]=>
  string(533) "
Founded in 1998, Unison is an independent private equity firm investing in the healthcare sector across Japan, Korea and Singapore, with an emphasis on the pharmaceutical sector. Unison 
&#nl
The post Lupin to sell its stake in Kyowa to Unison for $526m appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(533) "
Founded in 1998, Unison is an independent private equity firm investing in the healthcare sector across Japan, Korea and Singapore, with an emphasis on the pharmaceutical sector. Unison 
&#nl
The post Lupin to sell its stake in Kyowa to Unison for $526m appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(76) "https://www.pharmaceutical-business-review.com/news/lupin-sell-kyowa-unison/"
  ["blog_url"]=>
  string(76) "https://www.pharmaceutical-business-review.com/news/lupin-sell-kyowa-unison/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-11-15 05:49:10"
  ["create_at"]=>
  string(19) "2019-11-15 05:49:10"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Lupin to sell its stake in Kyowa to Unison for $526m

Founded in 1998, Unison is an independent private equity firm investing in the healthcare sector across Japan, Korea 

array(40) {
  [0]=>
  string(4) "6074"
  ["article_id"]=>
  string(4) "6074"
  [1]=>
  string(50) "Mylan, Pfizer announce Viatris as new company name"
  ["article_title"]=>
  string(50) "Mylan, Pfizer announce Viatris as new company name"
  [2]=>
  string(191) "Deriving its name from Latin, Viatris embodies the new company’s goal of providing a path—“VIA”—to three—“TRIS”—core goals: expandin"
  ["short_description"]=>
  string(191) "Deriving its name from Latin, Viatris embodies the new company’s goal of providing a path—“VIA”—to three—“TRIS”—core goals: expandin"
  [3]=>
  string(630) "
Deriving its name from Latin, Viatris embodies the new company’s goal of providing a path—“VIA”—to three—“TRIS”—core goals: expanding access to medicines, leading by innovating to meet patient needs, 
&#nl
The post Mylan, Pfizer announce Viatris as new company name appeared first on Pharmaceutical Business review.
&#nl"
  ["description"]=>
  string(630) "
Deriving its name from Latin, Viatris embodies the new company’s goal of providing a path—“VIA”—to three—“TRIS”—core goals: expanding access to medicines, leading by innovating to meet patient needs, 
&#nl
The post Mylan, Pfizer announce Viatris as new company name appeared first on Pharmaceutical Business review.
&#nl"
  [4]=>
  NULL
  ["image"]=>
  NULL
  [5]=>
  NULL
  ["big_image"]=>
  NULL
  [6]=>
  NULL
  ["feature_images"]=>
  NULL
  [7]=>
  NULL
  ["employer_id"]=>
  NULL
  [8]=>
  string(1) "1"
  ["category"]=>
  string(1) "1"
  [9]=>
  string(3) "RSS"
  ["added_by"]=>
  string(3) "RSS"
  [10]=>
  string(2) "10"
  ["status"]=>
  string(2) "10"
  [11]=>
  NULL
  ["highlight_status"]=>
  NULL
  [12]=>
  NULL
  ["hit_count"]=>
  NULL
  [13]=>
  string(2) "30"
  ["rss_id"]=>
  string(2) "30"
  [14]=>
  string(102) "https://www.pharmaceutical-business-review.com/news/mylan-pfizer-announce-viatris-as-new-company-name/"
  ["blog_url"]=>
  string(102) "https://www.pharmaceutical-business-review.com/news/mylan-pfizer-announce-viatris-as-new-company-name/"
  [15]=>
  string(19) "1970-01-01 07:30:00"
  ["add_date"]=>
  string(19) "1970-01-01 07:30:00"
  [16]=>
  NULL
  ["bythe"]=>
  NULL
  [17]=>
  NULL
  ["timestamp"]=>
  NULL
  [18]=>
  string(19) "2019-11-15 05:49:10"
  ["create_at"]=>
  string(19) "2019-11-15 05:49:10"
  [19]=>
  string(0) ""
  ["slug"]=>
  string(0) ""
}

Mylan, Pfizer announce Viatris as new company name

Deriving its name from Latin, Viatris embodies the new company’s goal of providing a path—“VIAâ